Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Alnylam
Alnylam
Alnylam Publishes Phase III ATTR-CM Data for Patisiran After FDA Rejection
Alnylam Publishes Phase III ATTR-CM Data for Patisiran After FDA Rejection
BioSpace
Alnylam
Patisiran
clinical trials
FDA
ATTR with cardiomyopathy
Flag link:
Interest in RNA Editing Accelerates as Therapies Approach the Clinic
Interest in RNA Editing Accelerates as Therapies Approach the Clinic
BioSpace
RNA editing
Alnylam
Shape Therapeutics
Eli Lilly
ProQR Therapeutics
Flag link:
Alnylam CEO, ‘disappointed’ with FDA’s Onpattro rejection, pivots to the future
Alnylam CEO, ‘disappointed’ with FDA’s Onpattro rejection, pivots to the future
Pharma Voice
Alnylam
Pharma CEOs
Yvonne Greenstreet
FDA
Onpattro
Flag link:
FDA denies expanded approval for Alnylam RNA drug
FDA denies expanded approval for Alnylam RNA drug
BioPharma Dive
Alnylam
FDA
RNA
Patisiran
ATTR amyloidosis
Flag link:
With FDA nod for rare disease drug Rivfloza, Novo Nordisk eyes showdown with Alnylam
With FDA nod for rare disease drug Rivfloza, Novo Nordisk eyes showdown with Alnylam
Fierce Pharma
Novo Nordisk
Rivfloza
FDA
primary hyperoxaluria type 1
RNAi
Alnylam
Flag link:
5 FDA decisions to watch in the fourth quarter
5 FDA decisions to watch in the fourth quarter
BioPharma Dive
FDA
Alnylam
Onpattro
ATTR amyloidosis
Vertex Pharmaceuticals
CRISPR Therapeutics
exa-cel
Bluebird Bio
Zynteglo
sickle cell disease
Bristol Myers Squibb
2seventy bio
Abecma
Multiple Myeloma
Amgen
Lumakras
non-small cell lung cancer
Pfizer
estrasimod
ulcerative colitis
Flag link:
Pfizer's 'entrenched' tafamidis franchise will be tough to challenge for Alnylam, BridgeBio: analysts
Pfizer's 'entrenched' tafamidis franchise will be tough to challenge for Alnylam, BridgeBio: analysts
Fierce Pharma
Pfizer
BridgeBio
Alnylam
FDA
clinical trials
ATTR-CM
physicians
tafamidis
Flag link:
Despite FDA doubts, Alnylam wins expert backing for Onpattro expansion into rare heart disease
Despite FDA doubts, Alnylam wins expert backing for Onpattro expansion into rare heart disease
Fierce Pharma
Alnylam
FDA
Onpattro
ATTR-CM
Flag link:
FDA Questions Efficacy of Alnylam’s Drug in ATTR-CM Ahead of Adcomm Meeting
FDA Questions Efficacy of Alnylam’s Drug in ATTR-CM Ahead of Adcomm Meeting
BioSpace
Alnylam
FDA
ATTR-CM
Onpattro
Flag link:
Roche Sees Return on $310M Investment with Alnylam’s Phase II Hypertension Win
Roche Sees Return on $310M Investment with Alnylam’s Phase II Hypertension Win
BioSpace
Alnylam
Roche
PAH
zilebesiran
clinical trials
Flag link:
Agios and Alnylam sign agreement for siRNA candidate
Agios and Alnylam sign agreement for siRNA candidate
Pharmaceutical Business Review
Agios Pharmaceuticals
Alnylam
siRNA
polycythemia vera
Flag link:
Roche, Alnylam Ink Potential $2.8B RNAi Partnership for Hypertension
Roche, Alnylam Ink Potential $2.8B RNAi Partnership for Hypertension
BioSpace
Roche
Alnylam
RNAi
hypertension
zilebesiran
Flag link:
AAIC: First Clinical Data from an RNAi Therapeutic for Alzheimer’s Continue to Impress
AAIC: First Clinical Data from an RNAi Therapeutic for Alzheimer’s Continue to Impress
BioSpace
AAIC
Alnylam
RNAi
Alzheimer's disease
ALN-APP
clinical trials
Flag link:
Alnylam and Regeneron report updated positive Phase I results of Alzheimer’s drug
Alnylam and Regeneron report updated positive Phase I results of Alzheimer’s drug
Clinical Trials Arena
Alnylam
clinical trials
ALN-APP
Alzheimer's disease
Flag link:
5 FDA decisions to watch in the third quarter
5 FDA decisions to watch in the third quarter
BioPharma Dive
FDA
SAGE Therapeutics
Biogen
zuranolone
Eisai
Leqembi
Sanofi
AstraZeneca
nirsevimab
Iveric Bio
Zimura
Alnylam
Onpattro
Flag link:
Moderna hits back at Alnylam's 'baseless' patent infringement claims
Moderna hits back at Alnylam's 'baseless' patent infringement claims
Fierce Pharma
Moderna Therapeutics
Alnylam
MRNA
vaccines
legals
Flag link:
Alnylam’s early Alzheimer’s results encourage, but company discloses new hurdle
Alnylam’s early Alzheimer’s results encourage, but company discloses new hurdle
BioPharma Dive
Alnylam
Regeneron
clinical trials
Alzheimer's disease
ALN-APP
Flag link:
Ionis, AstraZeneca's polyneuropathy med improved patients' quality of life in phase 3, teeing up battle with Alnylam
Ionis, AstraZeneca's polyneuropathy med improved patients' quality of life in phase 3, teeing up battle with Alnylam
Fierce Biotech
Ionis Pharmaceuticals
AstraZeneca
eplontersen
Alnylam
ATTR
Flag link:
AstraZeneca stays on course to challenge Alnylam with 66-week rare disease data
AstraZeneca stays on course to challenge Alnylam with 66-week rare disease data
Fierce Biotech
AstraZeneca
Ionis Pharmaceuticals
aplontersen
Alnylam
Onpattro
clinical trials
ATTRv-PN
Flag link:
JPM Day 1: Highlights
JPM Day 1: Highlights
BioSpace
JPMHC 2023
Sarepta Therapeutics
Biomarin
Alnylam
JNJ
Arrowhead Pharmaceuticals
Novartis
Bristol Myers Squibb
Flag link:
Pages
1
2
3
4
5
6
7
8
9
…
next ›
last »